Company / PP&E (Net)
BeOne Medicines Ltd. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.6B
FY2025
5-year range
$587.6M / $1.6B
FY2021-FY2025
Trend
+4.0%
vs FY2024
Sector context
#15 of 193
Health Care
What the data says
Among 193 Health Care companies, BeOne Medicines Ltd. is in the top 8% for pp&e (net). PP&E (Net) has increased for 9 consecutive years, from $26M in FY2016 to $1.6B in FY2025.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +35.6%. Top quartile in the Health Care sector.
Improved from $1.3B to $1.6B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +24.7%
- 5-Year CAGR
- +35.6%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 193This company $1.6B Sector average $777.6M
▼
+111.1% above sector average
Key checks
Key Insights
- BeOne Medicines Ltd.'s pp&e (net) has grown for 9 consecutive years.
- 5-year CAGR of +35.6%, indicating consistent growth.
- In FY2025, pp&e (net) increased 4.0% year-over-year.
- Ranks #15 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +4.0% |
| FY2024 | $1.6B | +19.2% |
| FY2023 | $1.3B | +56.5% |
| FY2022 | $845.9M | +44.0% |
| FY2021 | $587.6M | +64.3% |
| FY2020 | $357.7M | +47.6% |
| FY2019 | $242.4M | +54.3% |
| FY2018 | $157.1M | +151.0% |
| FY2017 | $62.6M | +140.9% |
| FY2016 | $26.0M | +292.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026